Gene therapy aims to stop painful swelling attacks in hereditary angioedema

NCT ID NCT05120830

Ongoing Disease control Sponsor: Intellia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene editing to lower a protein that triggers these attacks. The goal is to see if it is safe and can reduce how often attacks happen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY ANGIOEDEMA

Contacts and locations

Locations

Clinical Trial Site

Campbelltown, Australia
Clinical Trial Site

Grenoble, France
Clinical Trial Site

Lille, France
Clinical Trial Site

Paris, France
Clinical Trial Site

Berlin, Germany
Clinical Trial Site

Frankfurt, Germany
Clinical Trial Site

Amsterdam, Netherlands
Clinical Trial Site

Auckland, New Zealand
Clinical Trial Site

Cambridge, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.